{
  "id": 12162594,
  "title": "Vaxcyte skyrockets on ‘near best-case’ pneumococcal vaccine data",
  "url": "https://urgent.news/2026/10/05/vaxcyte-skyrockets-on-near-best-case-pneumococcal-vaccine-data",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-05T13:52:00.000Z",
  "source": {
    "name": "BioPharma Dive",
    "slug": "biopharma-dive",
    "url": "https://www.biopharmadive.com/news/vaxcyte-pneumococcal-vaccine-opus-study-results-prevnar-capvaxive/832095/"
  },
  "original_language": "en",
  "account": null,
  "summary": "The company’s next-generation shot surpassed Wall Street’s expectations by matching the effectiveness of vaccines from Pfizer and Merck on nearly all bacterial strains in the first of three Phase 3 trials.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 3,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Vaxcyte to present phase 3 trial data for vaccine candidate",
        "url": "https://urgent.news/2026/10/04/vaxcyte-to-present-phase-3-trial-data-for-vaccine-candidate",
        "published": "2026-10-04T21:04:37.000Z"
      },
      {
        "outlet": "Seeking Alpha News",
        "title": "Vaxcyte jumps on phase 3 data for pneumonia vaccine VAX-31",
        "url": "https://urgent.news/2026/10/05/vaxcyte-jumps-on-phase-3-data-for-pneumonia-vaccine-vax-31",
        "published": "2026-10-05T14:53:16.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}